Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer

BACKGROUND: Colorectal cancer is the third most common malignant disease and the second leading cause of death worldwide. Previous studies showed improved bioavailability and cytotoxicity of ginsenoside-modified nanostructured lipid carrier containing curcumin (G-NLC) in human colon cancer cell line...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Youngbae, Sym, Sun Jin, Yoo, Bong Kyu, Baek, Jeong-Heum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202259/
https://www.ncbi.nlm.nih.gov/pubmed/35695002
http://dx.doi.org/10.1177/15347354221105498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202259/
https://www.ncbi.nlm.nih.gov/pubmed/35695002
http://dx.doi.org/10.1177/15347354221105498

Ejemplares similares